Histiocytoses and Hematology
The major aim of our studies is to improve survival and reduce long-term sequelae in children affected by cancer and blood disorders, with focus on hematological disorders and the histiocytoses (hemophagocytic lymphohistiocytosis, HLH, and Langerhans cell histiocytosis, LCH).
Our goal is to develop better treatment regimens, and better diagnostic and monitoring tools. Our studies have resulted in significantly improved survival for patients affected by these disorders.
Research group leader:
With the ultimate goal to improve treatment and outcome, we also investigate underlying genetics, immunology and biology of the disorders. Our studies range from molecular biology, through cellular studies to clinical and epidemiological studies. They comprise the following main areas which are presented in detail.
- Hemophagocytic Lymphohistiocytosis (HLH)
- Langerhans Cell Histiocytosis (LCH)
- Acute leukemias
Désirée Gavhed, PhD, Research coordinator
Elisabet Bergsten, PhD, Research coordinator, Data manager
Ida Hed Myrberg, Statistician
Magdalini Lourda, PhD, Assistant professor
Nikolas Herold, MD, Dr. med, postdoc; Fellow in pediatrics
AnnaCarin Horne, MD, PhD, Senior researcher; Consultant
Selma Olsson Åkefeldt, MD, PhD; Pediatrician
Marie Meeths, MD, PhD; Fellow in pediatrics
Maja Ideström, MD, PhD; Senior Consultant
Frida Holm, PhD, Assistant professor
Bengt Fadeel, MD, PhD, Professor
Yenan Bryceson, PhD, Assistant professor
Mattias Svensson, PhD, Associate professor
Chengyun Zheng, MD, PhD; Head of Hematology, Second Hospital, Shandong Univ, Jinan, China
Evaldas Laurencikas, MD, PhD Neuroradiologist
Ulrika Kreicbergs, RN, PhD, Professor